Attendee search 

GfK Bridgehead is a global strategic healthcare consultancy that specializes in pricing and reimbursement, opportunity assessment, market access strategy, health economics, transaction support, valuation and due diligence.

Preferred partner for many major companies in the pharmaceutical, medical device, diagnostic and financial sectors.

Respected for bringing payer insights into R&D, portfolio, business development, commercialization and lifecycle strategies.

Renowned for qualitative and quantitative research capabilties.

A truly global organization, able to draw upon the expertise of 500 healthcare experts in more than 100 countries.

Conatus Pharmaceuticals Inc., a privately-held drug development company, is actively engaged in the development of first-in-class medicines to treat liver disease.  Liver disease affects hundreds of million people worldwide and can be caused by many different injuries to the liver including Hepatitis C and other viral infections, obesity, alcohol or autoimmune diseases

Emricasan (IDN-6556) is a first-in-class  oral small molecule compound to target apoptosis and treat liver fibrosis through a pan-caspase mechanism and is poised to enter Phase 3 registration studies in early 2013.

Emricasan is to be indicated for the treatment of HCV associated liver fibrosis in patients post orthotopic liver transplantation (POLT) to delay the progression of liver fibrosis to cirrhosis, and the treatment of acute liver failure in patients with underlying liver cirrhosis (ACLF) to improve transplant-free survival and decrease the incidence of progression to multi-organ failure.  Both diseases are potentially orphan indications.

Emricasan has completed the initial regulatory carcinogenicity study in rasH2 mice with an outcome of no drug related tumors observed.

Conatus has a broad portfolio of 128 issued patents plus pending applications protecting compounds and six gene families related to apoptosis that comprise viable drug targets; with exclusivity of emricasan franchise to 2028 w/o extensions

Emricasan’s initial ACLF and POLT orphan indications combined represent a potential revenue opportunity of ~1.6 billion in peak sales in US and EU and the estimated market launch is: ACLF (Q3 2016), POLT (Q4 2017).

Conatus is seeking a global or regional partner to advance Emricisan to the market.

Zosano Pharma (ZP), a spin-off of J&J, offers a fully-developed and validated transdermal drug-delivery platform to deliver small molecules, peptides, proteins and vaccines on a band-aid like patch with the efficacy of injectables.

Totally pain-free, the ZP patch offers quick onset of action, delivers with the efficacy of an injection and is stable at room temperature. It has been successfully tested with 30 compounds. The most advanced product is PTH for severe osteoporosis with completed Ph2 studies. Rights to PTH for select Asian countries have been granted to Asahi-Kasei Pharma, Japan.

ZP products are produced in its own GMP manufacturing facility at a low cost and offer attractive margins versus currently-marketed injectables.

ZP products are attractive to patients (pain-free & don't require refrigeration), payors (priced competitively versus marketed products) and pharma companies (for life cycle extension with ZP IP extending to 2027).

MacroGenics is a leader in the development of next-generation antibody therapeutics for the treatment of cancer, autoimmune disorders, and infectious disease. Using its proprietary platforms for cancer-stem cells, bi-specific antibodies (DARTs) and Fc-optimization, the company has generated a robust pipeline of clinical and pre-clinical programs. The company has multiple research and development collaborations with major pharmaceutical companies including Les Laboratoires Servier, Boehringer Ingelheim and Pfizer, Inc.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, oncology, as well as muscle disorders.  Partnering projects include: 1) R763 an Aurora Kinase inhibitor for oncology with Phase 2 results and 2)  R723 a selective Jak2 inhibitor in preclinical development for Thrombocytosis in RA, RA, and Myeloproliferative Diseases (hematology). 

Meda is a global specialty pharma company with products in over 120 countries worldwide and $1.9BUSD in sales.

Meda's primary growth strategy is search and acquire focusing on acquisitions aligned with our current verticals (allergy/respiratory; women and men's health; dermatology (EU); cardiovascular (EU); and pain and inflammation).

We tend towards low risk investments, hence, late stage products (e.g., successful completion of a Phase III) or marketed products. We avoid 505(b)(2) products unless there is a clear unmet need that is met by a highly differentiated product.

GLG Research partners with organizations seeking efficient, targeted connections to insight.

Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:

• 9 of the top 10 pharmaceutical and biotechnology companies
• More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
• 7 out of the top 10 global medical equipment companies
• Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world